Physician profile
Marvi Iqbal
NPI 1205015211
$4,566.73
in general payments reported to CMS, 2019-2025
23 companies · $1,051 in 2025
The $1,051 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $25.74 · 2021: $514 · 2022: $1,119 · 2023: $365 · 2024: $1,271 · 2025: $1,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,506 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,506.18 |
| Education | $182.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $974.45 | 2021-2025 | |
| Leo Pharma INC. | $568.50 | 2020-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $482.43 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Janssen Biotech, INC. | $471.65 | 2021-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $415.34 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $413.46 | 2021-2025 | Dupixent, Libtayo |
| Abbvie INC. | $347.98 | 2021-2025 | |
| Amgen INC. | $156.62 | 2022-2025 | Otezla |
| Sun Pharmaceutical Industries INC. | $106.79 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2022 | |
| Incyte Corporation | $80.79 | 2021-2024 | Opzelura |
| Arcutis Biotherapeutics, INC. | $80.74 | 2023-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $54.26 | 2022-2024 | |
| Epi Health, LLC | $53.75 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $52.53 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.19 | 2021-2025 | Cabtreo, Siliq, Jublia |
| Journey Medical Corporation | $35.40 | 2019-2022 | |
| Lilly USA, LLC | $34.35 | 2023-2024 | Taltz, Olumiant |
| Almirall LLC | $28.96 | 2025 | Seysara |
| Organon LLC | $28.46 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $24.43 | 2021 | |
| Dermavant Sciences, INC. | $17.65 | 2023 | Vtama |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvi Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.